Literature DB >> 15007349

Human monoclonal antibody-based quantification of group 2 grass pollen allergens.

Katharina Marth1, Margarete Focke, Sabine Flicker, Rudolf Valenta.   

Abstract

BACKGROUND: Grasses belong to the most potent allergen sources worldwide. Group 2 grass pollen allergens are recognized by more than 100 million allergic patients.
OBJECTIVE: The aim was to develop an assay for the specific detection and quantification of group 2 grass pollen allergens.
METHODS: We have isolated a monoclonal human IgE Fab specific for group 2 grass pollen allergens by combinatorial cloning from lymphocytes of a grass pollen-allergic patient. This Fab was converted into a complete human IgG1 antibody and used together with rPh1 p 2 to develop a competitive ELISA for the specific measurement of group 2 allergens. ELISA plate-bound purified recombinant human Ph1 p 2-specific IgG1 is incubated with a constant amount of biotinylated rPh1 p 2 competing with increasing concentrations of group 2 allergens to be determined. Defined concentrations of purified rPhl p 2 are used to establish a standard curve. The concentration of unlabeled group 2 allergens can thus be deduced from the displacement of biotinylated rPh1 p 2, which can be detected with peroxidase-labeled streptavidin.
RESULTS: The competition-ELISA measured rPh1 p 2 concentrations ranging from 10 ng/mL to 500 ng/mL and allowed to quantify group 2 allergens from 9 different grass families. The results were in good agreement with immunoblot data.
CONCLUSIONS: The described assay can be used for standardization of diagnostic and therapeutic vaccines as well as for the quantification of group 2 allergens in environmental samples.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15007349     DOI: 10.1016/j.jaci.2003.11.042

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

Review 1.  Immunologic, spectrophotometric and nucleic acid based methods for the detection and quantification of airborne pollen.

Authors:  William R Rittenour; Robert G Hamilton; Donald H Beezhold; Brett J Green
Journal:  J Immunol Methods       Date:  2012-02-03       Impact factor: 2.303

2.  A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.

Authors:  Katharina Marth; Isabella Breyer; Margarete Focke-Tejkl; Katharina Blatt; Mohamed H Shamji; Janice Layhadi; Anna Gieras; Ines Swoboda; Domen Zafred; Walter Keller; Peter Valent; Stephen R Durham; Rudolf Valenta
Journal:  J Immunol       Date:  2013-02-25       Impact factor: 5.422

3.  Allergen Microarray Indicates Pooideae Sensitization in Brazilian Grass Pollen Allergic Patients.

Authors:  Priscila Ferreira de Sousa Moreira; Katharina Gangl; Francisco de Assis Machado Vieira; Leandro Hideki Ynoue; Birgit Linhart; Sabine Flicker; Helmut Fiebig; Ines Swoboda; Margarete Focke-Tejkl; Ernesto Akio Taketomi; Rudolf Valenta; Verena Niederberger
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

4.  Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines.

Authors:  Milena Weber; Katarzyna Niespodziana; Birgit Linhart; Angela Neubauer; Hans Huber; Rainer Henning; Rudolf Valenta; Margarete Focke-Tejkl
Journal:  J Allergy Clin Immunol       Date:  2017-05-31       Impact factor: 10.793

5.  A proteomic style approach to characterize a grass mix product reveals potential immunotherapeutic benefit.

Authors:  Alan Bullimore; Nicola Swan; Wemimo Alawode; Murray Skinner
Journal:  World Allergy Organ J       Date:  2011-09-03       Impact factor: 4.084

Review 6.  Pollen Allergens for Molecular Diagnosis.

Authors:  Isabel Pablos; Sabrina Wildner; Claudia Asam; Michael Wallner; Gabriele Gadermaier
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.